Braxia Scientific Faces Challenges In Accessing Public Market Capital, Reports Q1 Loss
Braxia Scientific Faces Challenges In Accessing Public Market Capital, Reports Q1 Loss
Braxia Scientific Corp. (OTC:BRAXF), owner of ketamine therapy clinics and KetaMD telemedicine services for depression and related disorders, has shared its interim financial statements for the three months ended June 30, 2023.
布拉夏科学公司(场外交易：BRAXF)，氯胺酮治疗诊所和科塔玛远程医疗服务对于抑郁症和相关疾病，已经分享了截至2023年6月30日的三个月的中期财务报表。
In numbers:
在数字方面：
-
Cash held was $636.483 (CA$861,393) as of June 30, compared to $1.08 million by March 31, 2023 and $5.67 million by June 30, 2022.
-
Quarterly revenue of $64.783, compared to $79.263 in the same period in 2022. Revenue's 44% YoY increase ($443,490 vs. $308,490) was eclipsed by higher cost of sales ($378,707 now vs. $229,227 then.)
-
Quarterly operating expenses totaled $654.771, an almost 17% decrease from $783.859 in 2022's comparable period.
-
Quarterly net loss of $592,785, around 18% down from the $715,878 net loss of the comparable period in 2022.
-
Accumulated deficit of $86.3 million by June 30, 2023 compared to $76.7 million by June 30, 2022.
-
持有的现金截至6月30日为636.483美元(861,393加元)，而2023年3月31日为108万美元，2022年6月30日为567万美元。
-
季度收入64.783美元，而2022年同期为79.263美元。营收同比增长44%(443,490美元比308,490美元)被更高的销售成本(现在是378,707美元，当时是229,227美元)盖过了。
-
季刊运营费用总额为654.771美元，较2022年S同期的783.859美元减少了近17%。
-
季刊净亏损为592,785美元，较2022年同期的715,878美元净亏损约18%。
-
累计赤字到2023年6月30日为8,630万美元，而到2022年6月30日为7,670万美元。
Together with the financial statements, the company's management published a discussion and analysis document regarding the quarter's results.
与财务报表一起，公司管理层发布了一份讨论与分析有关本季度业绩的文件。
CEO Dr. Roger McIntyre says that, while Braxia continues to face challenges "including in accessing capital through public markets," the fiscal year's first quarter brought in increasing clinical demand from new referrals for ketamine treatments.
首席执行官罗杰·麦金太尔博士他说，虽然Bracia继续面临挑战，“包括通过公开市场获得资本”，但本财年第一季度带来了越来越多的对氯胺酮治疗的新转诊的临床需求。
This has in turn increased Braxia's patient base and treatment volumes across its clinics, a goal the company is taking ahead along with making "further progress" in reducing expenses and improving efficiencies.
这反过来又增加了Bracia的患者基础和整个诊所的治疗量，该公司正在推进这一目标，同时在降低费用和提高效率方面取得“进一步进展”。
See Also: Ketamine Therapy At Your Doorstep, Growing Number Of Clinics Offer This Treatment Option
另见：氯胺酮疗法在家门口，越来越多的诊所提供这种治疗选择
As for potential strategic partnerships within the context of a "challenging environment" in capital access, McIntyre says the team is currently involved in several discussions.
至于潜在的战略合作伙伴关系，在资本获取的“具有挑战性的环境”的背景下，麦金太尔说，该团队目前正在参与几个讨论。
"The company maintains its priorities and growth objectives. However, it also continues to look to access alternative sources of capital as well as seek other partnerships to support our growth objectives," he acknowledged. "If we are unable to raise additional funding in the short term, we will look at alternate courses of actions including, but not limited to, further cost reductions, restructuring and the potential scaling back of clinic locations."
“该公司维持其优先事项和增长目标。然而，它也继续寻求其他资金来源，以及寻求其他合作伙伴关系，以支持我们的增长目标，”他承认。如果我们无法在短期内筹集更多资金，我们将考虑其他行动方案，包括但不限于进一步降低成本、重组和可能缩减诊所地点。
Interested in other natural medicines markets? Our acclaimed Cannabis Capital Conference is coming up! Whether to close your deals or just get acquainted with the sector's best, come join us this Sept. 27-28 in Chicago for our 17th edition! Tickets HERE.
对其他天然药物市场感兴趣吗？我们广受好评的大麻之都会议马上就要到了！无论是完成您的交易，还是只是了解行业最好的产品，请于今年9月加入我们的行列。27-28在芝加哥为我们的第17届！门票在这里。
Photo: Benzinga edit with photo by Andrea Piacquadio by Pexels and DanielTahar on Wikimedia Commons.
图片：Benzinga编辑由Pexels和DanielTahar在Wikimedia Commons上由Andrea Piacquadio拍摄